$76.06 Billion T-Cell Immunotherapy Markets - Global Forecast to 2025 with Cumulative Impact of COVID-19 - ResearchAndMarkets.com
Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)
Last adaptimmune therapeutics plc - american depositary shares earnings: 5/9 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.adaptimmune.com/phoenix.zhtml?c=253991&p=irol-newsarticle&id=2255800
Company Research
Source: Business Wire
DUBLIN--(BUSINESS WIRE)--The "T-Cell Immunotherapy Market Research Report by Mechanism Of Action, by Product Class - Global Forecast to 2025 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.The Global T-Cell Immunotherapy Market is expected to grow from USD 37,168.68 Million in 2019 to USD 76,066.68 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 12.67%.Company Usability Profiles: The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global T-Cell Immunotherapy Market including Adaptimmune Therapeutics, Autolus, Bluebird Bio, CARsgen Therapeutics, Celgene, Cellectis, Innovative Cellular Therapeutics, Novartis, and Sinobioway Cell Therapy.FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the T-Cell Immunotherapy Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and
Show less
Read more
Impact Snapshot
Event Time:
ADAP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADAP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADAP alerts
High impacting Adaptimmune Therapeutics plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ADAP
News
- Garry Menzel joins GHO Capital as Operating Partner [Yahoo! Finance]Yahoo! Finance
- Adaptimmune (ADAP) Down on End of Collaboration With Roche [Yahoo! Finance]Yahoo! Finance
- Adaptimmune falls as Roche strategic collaboration ends [Seeking Alpha]Seeking Alpha
- Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated [Yahoo! Finance]Yahoo! Finance
- Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet [Yahoo! Finance]Yahoo! Finance
ADAP
Sec Filings
- 4/22/24 - Form ARS
- 4/12/24 - Form 8-K
- 4/11/24 - Form DEF
- ADAP's page on the SEC website